Skip to Content

Daunorubicin liposomal Disease Interactions

There are 3 disease interactions with daunorubicin liposomal:

Major

Daunorubicin (applies to daunorubicin liposomal) congestive heart failure

Major Potential Hazard, Moderate plausibility.

Daunorubicin can cause myocardial toxicity leading to congestive heart failure. Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure. The benefit-to-risk ratio of daunorubicin therapy in such patients should be weighed before starting treatment. The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of daunorubicin exceeds 550/mg/m2. An electrocardiogram and/or determination of systolic ejection fraction prior to each course of therapy is recommended.

References

  1. Ferrans VJ "Overview of cardiac pathology in relation to anthracycline cardiotoxicity." Cancer Treat Rep 62 (1978): 955-61
  2. Al-Ismail SA, Parry DH, Whittaker JA "Anthracycline cardiotoxicity and acute myelogenous leukaemia." Br Med J 1 (1977): 815
  3. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM "Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases." Am J Med 62 (1977): 200-8
  4. Harrison DT, Sanders LA "Letter: Pericarditis in a case of early daunorubicin cardiomyopathy." Ann Intern Med 85 (1976): 339-41
  5. Ainger LE, Bushore J, Johnson WW, Ito J "Daunomycin: a cardiotoxic agent." J Natl Med Assoc 63 (1971): 261-7
  6. Malhotra OP, Talwar KK, Chopra P, Kumar R "Erythroleukaemia and daunorubicin-induced cardiotoxicity in a young boy." Br J Clin Pract 44 (1990): 633-4
  7. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES "Cardiac ultrastructural changes induced by daunorubicin therapy." Cancer 32 (1973): 771-88
  8. Von Hoff DD, Layard M "Risk factors for development of daunorubicin cardiotoxicity." Cancer Treat Rep 65 Suppl 4 (1981): 19-23
  9. Kajihara H, Yokozaki H, Yamahara M, Kadomoto Y, Tahara E "Anthracycline induced myocardial damage. An analysis of 16 autopsy cases." Pathol Res Pract 181 (1986): 434-41
  10. "Daunorubicin and the heart." Br Med J 4 (1974): 431-2
  11. Mhatre R, Herman E, Huidobro A, Waravdekar V "The possible relationship between metabolism and cardiac toxicity of duanomycin and related compounds." J Pharmacol Exp Ther 178 (1971): 216-22
View all 11 references
Major

Daunorubicin (applies to daunorubicin liposomal) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Daunorubicin can induce severe myelosuppression at therapeutic doses. The use of daunorubicin may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with daunorubicin. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc, Boulder, CO.
  2. "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Major

Daunorubicin liposomal (applies to daunorubicin liposomal) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bleeding, Bone Marrow Depression/Low Blood Counts, Fever

Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of this drug. Therapy with daunorubicin hydrochloride should not be started in patients with preexisting-existing drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage.

References

  1. "Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc, Boulder, CO.

Daunorubicin liposomal drug interactions

There are 429 drug interactions with daunorubicin liposomal

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.